[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-336662-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-336662-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","clinical-insights-into-nanomedicine-and-biosafety-advanced-therapeutic-approaches-for-common-urological-cancers-review","Clinical insights into nanomedicine and biosafety - advanced therapeutic approaches for common urological cancers - Review","","Urological cancers of the prostate, bladder, and kidney remain prevalent and often lethal, and existing therapies are constrained by side effects, recurrence, resistance, high costs, and reduced quality of life. The review describes how nanotechnology supports improved diagnostics, targeted drug delivery, controlled release, and multimodal imaging across key urological malignancies. It summarizes nanoparticle roles in prostate radiosensitization and surgical guidance, bladder residence-time enhancement for intravesical therapy, and renal approaches including potentiation of tyrosine kinase inhibitors, immunotherapy, and gene/vector effects. Biosafety profiles look favorable, but clinical translation is limited, requiring further trials to enable earlier detection and more tailored interventions.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/clinical-insights-into-nanomedicine-and-biosafety-advanced-therapeutic-approaches-for-common-urological-cancers-review/336662/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/clinical-insights-into-nanomedicine-and-biosafety-advanced-therapeutic-approaches-for-common-urological-cancers-review/336662.png","ImageObject",300,407,{"name":42,"@type":43},"Asher","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are current urological cancer treatments considered inadequate?","Question",{"text":63,"@type":64},"They are limited by major drawbacks such as side effects, recurrence, therapeutic resistance, high costs, and reduced quality of life, along with issues in insensitivity and specificity of existing theranostic strategies.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does nanomedicine address prostate cancer challenges?",{"text":68,"@type":64},"Nanoparticles can improve delineation and radiosensitization in radiation therapy, provide fluorescent guidance in surgery, and enhance chemotherapy penetration in metastatic disease.",{"name":70,"@type":61,"acceptedAnswer":71},"What does the review say about biosafety and clinical translation?",{"text":72,"@type":64},"Biosafety assessments show favorable profiles, but clinical translation remains limited, indicating the need for further trials to validate broader use.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},336662,1790343498,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":111,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","TYPE Review  \nPUBLISHED 13 August 2024  \nDOI 10.3389/fonc.2024.1438297  \nOPEN ACCESS  \nEDITED BY  \nHamed Ahmadi,  \nUniversity of Minnesota Medical Center, United States  \nREVIEWED BY  \nSayeda Yasmin-Karim,  \nHarvard Medical School, United States  \nR. C. Koumar,  \nYenepoya University, India  \n*CORRESPONDENCE Hossein Motedayyen  \n [hmotedayyen@gmail.com](hmotedayyen@gmail.com)[ ](hmotedayyen@gmail.com)Reza Arefnezhad  \n [Reza.aref1374@gmail.com](Reza.aref1374@gmail.com)  \nRECEIVED 25 May 2024  \nACCEPTED 29 July 2024  \nPUBLISHED 13 August 2024  \nCITATION  \nFattahi MR, Dehghani M, Paknahad S, Rahiminia S, Zareie D, Hoseini B, Oroomi TR, Motedayyen H and Arefnezhad R (2024) Clinical insights into nanomedicine and biosafety: advanced therapeutic approaches for common urological cancers.  \nFront. Oncol. 14:1438297 .  \ndoi: 10.3389/fonc.2024.1438297  \nCOPYRIGHT  \n© 2024 Fattahi, Dehghani, Paknahad, Rahiminia, Zareie, Hoseini, Oroomi, Motedayyen and Arefnezhad. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nClinical insights into  \nnanomedicine and biosafety: advanced therapeutic approaches for common urological cancers  \nMohammad Reza Fattahi 1, Mansoureh Dehghani 2, Somayyeh Paknahad 3, Shafa Rahiminia 4, Deniz Zareie 5, Behzad Hoseini 6, Tahmineh Rajaee Oroomi 7, Hossein Motedayyen 8* and Reza Arefnezhad 9,10*  \n1Student Research Committee, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran, 2 Reza Radiotherapy and Oncology Center (RROC), Mashhad, Iran, 3 Legal Medicine Organization, Tehran, Iran, 4School of Medicine, Guilan University of Medical Sciences, Rasht, Iran, 5School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran, 6School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran, 7 Islamic Azad Tehran University of Medical Sciences, Tehran, Iran, 8Autoimmune Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran, 9Coenzyme R Research Institute, Tehran, Iran, 10Shiraz University of Medical Sciences, Shiraz, Iran  \nUrological cancers including those of the prostate, bladder, and kidney, are prevalent and often lethal malignancies besides other less common ones like testicular and penile cancers. Current treatments have major limitations like side effects, recurrence, resistance, high costs, and poor quality of life . Nanotechnology offers promising solutions through enhanced diagnostic accuracy, targeted drug delivery, controlled release, and multimodal imaging. This review reﬂects clinical challenges and nanomedical advances across major urological cancers. In prostate cancer, nanoparticles improve delineation and radiosensitization in radiation therapy, enable ﬂuorescent guidance in surgery, and enhance chemotherapy penetration in metastatic disease. Nanoparticles also overcome bladder permeability barriers to increase the residence time of intravesical therapy and chemotherapy agents. In renal cancer, nanocarriers potentiate tyrosine kinase inhibitors and immunotherapy while gene vectorsand zinc oxide nanoparticles demonstrate antiproliferative effects. Across modalities, urological applications of nanomedicine include polymeric, liposomal, and metal nanoparticles for targeted therapy, prodrug delivery, photodynamic therapy, and thermal ablation. Biosafety assessments reveal favorable proﬁles but clinical translation remains limited, necessitating further trials. In conclusion, nanotechnology holds signiﬁcant potential for earlier detection, precise intervention, and tailored treatment of uro logical malignancies, warr","cbCairl7yihN9hVl","https://ap.wps.com/l/cbCairl7yihN9hVl","pdf",2717820,21,"English","# Introduction\n# Limitations of current urological cancer treatments\n# Unmet need for new diagnostic and therapeutic paradigms\n# Nanomedicine advances in urological cancers","[{\"question\":\"Why are current urological cancer treatments considered inadequate?\",\"answer\":\"They are limited by major drawbacks such as side effects, recurrence, therapeutic resistance, high costs, and reduced quality of life, along with issues in insensitivity and specificity of existing theranostic strategies.\"},{\"question\":\"How does nanomedicine address prostate cancer challenges?\",\"answer\":\"Nanoparticles can improve delineation and radiosensitization in radiation therapy, provide fluorescent guidance in surgery, and enhance chemotherapy penetration in metastatic disease.\"},{\"question\":\"What does the review say about biosafety and clinical translation?\",\"answer\":\"Biosafety assessments show favorable profiles, but clinical translation remains limited, indicating the need for further trials to validate broader use.\"}]","Clinical insights into nanomedicine and biosafety - advanced therapeutic approaches for common urological cancers - Review | PDF",1790016083,53,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5d88e666bcea755acb1c63a42a9add8c.webp",983,1389,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9ba986edd840082f5c859d053ba9c67d.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9cb401df6a3eb84527a332d8a6f9f635.webp",981,1386,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6492d0e8f102e9df498a4c3068a0ac95.webp",980,1385]